Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Amine Kasmi, Sophie Rigaudeau et al.|Nature Medicine|2024Cited by 109
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialAurore Perrot, Jill Corre, Cyrille Touzeau et al.|Blood|2025Cited by 34
Efficacy and safety profile of long‐term exposure to lenalidomide in patients with recurrent multiple myelomaGuillemette Fouquet, Xavier Leleu, Stéphanie Tardy et al.|Cancer|2013Cited by 31
IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's MacroglobulinaemiaEileen M. Boyle, Xavier Leleu, Salomon Manier et al.|Clinical Cancer Research|2016Cited by 10
IgA Hevylite® Test As a Surrogate to Serum Protein Electrophoresis (SPEP) or Nephelometry in the Management of IgA MyelomaEileen M. Boyle, Xavier Leleu, Philip Young et al.|Blood|2012Cited by 1